PRESCIENT THERAPEUTICS LIMITED - Announcements

Market Cap $37.04M Add to my watchlist

Prescient Therapeutics Limited is an Australia-based clinical-stage oncology company. The... Prescient Therapeutics Limited is an Australia-based clinical-stage oncology company. The Company is engaged in the development of personalized medicine approaches to cancer, including targeted and cellular therapies. Its product pipeline includes PTX-100, PTX-200, OmniCAR, CellPryme-M and CellPryme-A. PTX-100 is a compound with the ability to block a cancer growth enzyme, geranylgeranyl transferase-1 (GGT-1). PTX-100 is in Phase Ib expansion cohort study in T cell lymphomas. PTX-200 is a PH domain inhibitor that inhibits a tumor survival pathway, Akt. PTX-200 is in Phase Ib/II trial in relapsed and refractory AML. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single-cell product. CellPryme-M is a platform for enhancing cell therapies by producing cells with superior phenotypes. CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy.More

Announcements

Filter Results

All Price Sensitive Only

PTX	PTXO Options Update		03/07/18	128.15KB	Share
PTX	Appendix 3B		22/06/18	226.82KB	Share
PTX	Letter to PTXO Option Holders		31/05/18	1.41MB	Share
PTX	Section 708A Cleansing Notice and Appendix 3B		11/05/18	256.62KB	Share
PTX	CSO Precision Medicine Presentation		01/05/18	3.26MB	Share
PTX	March 2018 Appendix 4C - Quarterly	PRICE SENSITIVE	23/04/18	439.63KB	Share
PTX	Response to Aware Query	PRICE SENSITIVE	12/04/18	682.86KB	Share
PTX	PTX-200 Phase 1b Breast Cancer Trial Results	PRICE SENSITIVE	10/04/18	153.25KB	Share
PTX	Appendix 3B		06/04/18	522.07KB	Share
PTX	March 2018 Investor Presentation	PRICE SENSITIVE	19/03/18	2.64MB	Share
PTX	Section 708A Cleansing Notice and Appendix 3B		14/03/18	736.79KB	Share
PTX	Appendix 4D and Half Year Financial Report	PRICE SENSITIVE	27/02/18	588.3KB	Share
PTX	Receipt of R&D Tax Rebate	PRICE SENSITIVE	01/02/18	96.13KB	Share
PTX	December 2017 Appendix 4C - Quarterly	PRICE SENSITIVE	31/01/18	214.8KB	Share
PTX	Clinical Trial Updates	PRICE SENSITIVE	29/01/18	108.02KB	Share
PTX	Prescient Presenting at Biotech Showcase		10/01/18	100.7KB	Share
PTX	CSO named among Top 20 Translational Researchers by Nature		20/12/17	103.41KB	Share
PTX	Clinical Hold Lifted on PTX-200 Breast Cancer Trial	PRICE SENSITIVE	11/12/17	189.03KB	Share
PTX	Edison Investment Research - Clinical Development Update		21/11/17	96.73KB	Share
PTX	Results of Annual General Meeting		20/11/17	400.58KB	Share
PTX	AGM Chairman Address		20/11/17	232.54KB	Share
PTX	AGM Presentation		20/11/17	1.13MB	Share
PTX	PTX to resume Clinical Trial of PTX-200 in Ovarian Cancer	PRICE SENSITIVE	06/11/17	190.6KB	Share
PTX	September 2017 Appendix 4C - Quarterly	PRICE SENSITIVE	27/10/17	420.15KB	Share
PTX	Notice of Annual General Meeting/Proxy Form		20/10/17	1.1MB	Share
PTX	Investor Presentation - October 2017		05/10/17	3.24MB	Share
PTX	PTX-100 to Re-enter Trials in Hematology Niche	PRICE SENSITIVE	03/10/17	167.41KB	Share
PTX	Prescient to resume AML trial	PRICE SENSITIVE	04/09/17	234.23KB	Share
PTX	Appendix 4G and Corporate Governance Statement		29/08/17	1.27MB	Share
PTX	Appendix 4E and 2017 Annual Report	PRICE SENSITIVE	29/08/17	1.02MB	Share
PTX	Investor Newsletter - August 2017		01/08/17	815.37KB	Share
PTX	June 2017 Appendix 4C - Quarterly	PRICE SENSITIVE	26/07/17	426.92KB	Share
PTX	Paul Hopper moves to Non-Executive Director		30/06/17	176.66KB	Share
PTX	Gold Coast Investor Conference Presentation		22/06/17	2.42MB	Share
PTX	Novel PTX-100 Cancer Approach Published in Nature	PRICE SENSITIVE	19/06/17	252.6KB	Share
PTX	Appendix 3B		31/05/17	807.4KB	Share
PTX	Clinical Trial Update	PRICE SENSITIVE	29/05/17	99.59KB	Share
PTX	PTX Broker Presentation	PRICE SENSITIVE	16/05/17	2.62MB	Share
PTX	European Patent Granted for PTX-200	PRICE SENSITIVE	12/05/17	111.75KB	Share
PTX	Kansas University Joins PTX's AML Trial	PRICE SENSITIVE	08/05/17	297.41KB	Share
PTX	FDA Grants Orphan Drug Designation for PTX-200 in AML	PRICE SENSITIVE	01/05/17	137.25KB	Share
PTX	March 2017 Appendix 4C - Quarterly	PRICE SENSITIVE	27/04/17	139.83KB	Share
PTX	AML Update - Conference call with Principal Investigator		20/04/17	302.61KB	Share
PTX	Successful Completion of Phase 1b Breast Cancer Trial	PRICE SENSITIVE	06/04/17	140.85KB	Share
PTX	Trading Halt	PRICE SENSITIVE	04/04/17	319.66KB	Share
PTX	Response to ASX Price Query	PRICE SENSITIVE	28/03/17	574.71KB	Share
PTX	Three Additional US Patents Granted	PRICE SENSITIVE	16/03/17	95.03KB	Share
PTX	ROTH Conference Presentation		15/03/17	3.28MB	Share
PTX	PTX presentation for 29th Annual ROTH Conference		15/03/17	94.13KB	Share
PTX	First Cohort Successfully Completed in Phase 1b/2 AML Trial	PRICE SENSITIVE	08/03/17	193.1KB	Share
PTX	PTX to present at 29th Annual ROTH Conference		03/03/17	108.43KB	Share
PTX	Appendix 4D and Half Year Financial Report	PRICE SENSITIVE	23/02/17	596.12KB	Share
PTX	December 2016 Appendix 4C - Quarterly	PRICE SENSITIVE	25/01/17	158.04KB	Share
PTX	Investor Presentation January 2017		11/01/17	2.87MB	Share
PTX	PTX to present at Biotech Showcase 2017 in San Francisco		11/01/17	93.19KB	Share
PTX	Change of Director's Interest Notices x4		21/12/16	469.28KB	Share
PTX	Section 708A Cleansing Notice and Appendix 3B		21/12/16	650.69KB	Share
PTX	Change of Registry Address		16/12/16	101.6KB	Share
PTX	First Patient Dosed on Phase 1b/2 AML Trial	PRICE SENSITIVE	14/12/16	111KB	Share
PTX	Phase 1b/2 Ovarian Trial Commences 2nd Dose Escalation	PRICE SENSITIVE	08/12/16	408.73KB	Share
PTX	Results of Annual General Meeting		30/11/16	314.8KB	Share
PTX	Change of Director's Interest Notice		09/11/16	263.27KB	Share
PTX	Receipt of R&D Tax Rebate-PTX.AX	PRICE SENSITIVE	02/11/16	205.19KB	Share
PTX	Notice of Annual General Meeting/Proxy Form-PTX.AX		28/10/16	1.48MB	Share
PTX	September 2016 Appendix 4C - Quarterly-PTX.AX	PRICE SENSITIVE	28/10/16	395.63KB	Share
PTX	Response to ASX Price Query-PTX.AX	PRICE SENSITIVE	19/10/16	716.25KB	Share
PTX	First patient at Moffitt dosed in Phase 1b/2 breast trial-PTX.AX	PRICE SENSITIVE	26/09/16	225.64KB	Share
PTX	Rodman & Renshaw Global Investment conference Presentation-PTX.AX		13/09/16	3.78MB	Share
PTX	PTX presents at Rodman & Renshaw Investment conference-PTX.AX		13/09/16	272.42KB	Share
PTX	Appendix 3B-PTX.AX		12/09/16	553.51KB	Share
PTX	Appendix 4G and Corporate Governance Statement-PTX.AX		31/08/16	1.1MB	Share
PTX	Appendix 4E and 2016 Annual Report-PTX.AX	PRICE SENSITIVE	31/08/16	800.39KB	Share
PTX	Section 708A Cleansing Notice and Appendix 3B-PTX.AX		16/08/16	337.26KB	Share
PTX	USPTO Grants Allowances for Two PTX-200 Patents-PTX.AX	PRICE SENSITIVE	04/08/16	269.27KB	Share
PTX	Change of Director's Interest Notice-PTX.AX		27/07/16	266.91KB	Share
PTX	Change to exercise price of options-PTX.AX	PRICE SENSITIVE	20/07/16	218.84KB	Share
PTX	Change in substantial holding-PTX.AX		20/07/16	132.27KB	Share
PTX	Amended Share Trading Policy-PTX.AX		20/07/16	438.69KB	Share
PTX	June 2016 Appendix 4C - Quarterly-PTX.AX	PRICE SENSITIVE	20/07/16	197.07KB	Share
PTX	Section 708A Cleansing Notice and Appendix 3B-PTX.AX		18/07/16	906.46KB	Share
PTX	Shortfall Placement Oversubscribed-PTX.AX		12/07/16	157.86KB	Share
PTX	Change in substantial holding for PTX,PTX-AEF.AX		07/07/16		Share
PTX	Change in substantial holding for PTX,PTX-AEF.AX		07/07/16	247.35KB	Share
PTX	Change in substantial holding-PTX.AX		05/07/16	221.72KB	Share
PTX	Ceasing to be a substantial holder-PTX.AX		01/07/16	103.46KB	Share
PTX	Change of Director's Interest Notices x2-PTX.AX		01/07/16	301.56KB	Share
PTX	Completion of Entitlement Issue Allotment and Appendix 3B-PTX.AX		30/06/16	197.01KB	Share
PTX	Entitlement Offer Closure and Shortfall Notification-PTX.AX		29/06/16	238.32KB	Share
PTX	Becoming a substantial holder from AEF,AEF-PTX.AX		28/06/16		Share
PTX	Becoming a substantial holder from AEF,AEF-PTX.AX		28/06/16	336.56KB	Share
PTX	Becoming a substantial holder-PTX.AX		24/06/16	114.94KB	Share
PTX	Change in substantial holding-PTX.AX		24/06/16		Share
PTX	Change in substantial holding-PTX.AX		24/06/16	267.35KB	Share
PTX	Tranche 2 Capital Raising Complete and Appendix 3B-PTX.AX		23/06/16		Share
PTX	Tranche 2 Capital Raising Complete and Appendix 3B-PTX.AX		23/06/16	371.92KB	Share
PTX	Results of Meeting-PTX.AX		22/06/16	354.47KB	Share
PTX	Extension of Closing Date of Entitlement Offer-PTX.AX		16/06/16	78.97KB	Share
PTX	Yale Joins PTX's Phase 1b/2 AML Clinical Trial-PTX.AX	PRICE SENSITIVE	15/06/16	269.24KB	Share
PTX	Despatch of Pro-rata Rights Issue Offer Documents-PTX.AX		06/06/16	217.72KB	Share
PTX	Replacement Entitlement Offer Prospectus-PTX.AX	PRICE SENSITIVE	03/06/16	1.14MB	Share

PTX PTXO Options Update
03/07/18		128.15KB	Share
PTX Appendix 3B
22/06/18		226.82KB	Share
PTX Letter to PTXO Option Holders
31/05/18		1.41MB	Share
PTX Section 708A Cleansing Notice and Appendix 3B
11/05/18		256.62KB	Share
PTX CSO Precision Medicine Presentation
01/05/18		3.26MB	Share
PTX March 2018 Appendix 4C - Quarterly
23/04/18	PRICE SENSITIVE	439.63KB	Share
PTX Response to Aware Query
12/04/18	PRICE SENSITIVE	682.86KB	Share
PTX PTX-200 Phase 1b Breast Cancer Trial Results
10/04/18	PRICE SENSITIVE	153.25KB	Share
PTX Appendix 3B
06/04/18		522.07KB	Share
PTX March 2018 Investor Presentation
19/03/18	PRICE SENSITIVE	2.64MB	Share
PTX Section 708A Cleansing Notice and Appendix 3B
14/03/18		736.79KB	Share
PTX Appendix 4D and Half Year Financial Report
27/02/18	PRICE SENSITIVE	588.3KB	Share
PTX Receipt of R&D Tax Rebate
01/02/18	PRICE SENSITIVE	96.13KB	Share
PTX December 2017 Appendix 4C - Quarterly
31/01/18	PRICE SENSITIVE	214.8KB	Share
PTX Clinical Trial Updates
29/01/18	PRICE SENSITIVE	108.02KB	Share
PTX Prescient Presenting at Biotech Showcase
10/01/18		100.7KB	Share
PTX CSO named among Top 20 Translational Researchers by Nature
20/12/17		103.41KB	Share
PTX Clinical Hold Lifted on PTX-200 Breast Cancer Trial
11/12/17	PRICE SENSITIVE	189.03KB	Share
PTX Edison Investment Research - Clinical Development Update
21/11/17		96.73KB	Share
PTX Results of Annual General Meeting
20/11/17		400.58KB	Share
PTX AGM Chairman Address
20/11/17		232.54KB	Share
PTX AGM Presentation
20/11/17		1.13MB	Share
PTX PTX to resume Clinical Trial of PTX-200 in Ovarian Cancer
06/11/17	PRICE SENSITIVE	190.6KB	Share
PTX September 2017 Appendix 4C - Quarterly
27/10/17	PRICE SENSITIVE	420.15KB	Share
PTX Notice of Annual General Meeting/Proxy Form
20/10/17		1.1MB	Share
PTX Investor Presentation - October 2017
05/10/17		3.24MB	Share
PTX PTX-100 to Re-enter Trials in Hematology Niche
03/10/17	PRICE SENSITIVE	167.41KB	Share
PTX Prescient to resume AML trial
04/09/17	PRICE SENSITIVE	234.23KB	Share
PTX Appendix 4G and Corporate Governance Statement
29/08/17		1.27MB	Share
PTX Appendix 4E and 2017 Annual Report
29/08/17	PRICE SENSITIVE	1.02MB	Share
PTX Investor Newsletter - August 2017
01/08/17		815.37KB	Share
PTX June 2017 Appendix 4C - Quarterly
26/07/17	PRICE SENSITIVE	426.92KB	Share
PTX Paul Hopper moves to Non-Executive Director
30/06/17		176.66KB	Share
PTX Gold Coast Investor Conference Presentation
22/06/17		2.42MB	Share
PTX Novel PTX-100 Cancer Approach Published in Nature
19/06/17	PRICE SENSITIVE	252.6KB	Share
PTX Appendix 3B
31/05/17		807.4KB	Share
PTX Clinical Trial Update
29/05/17	PRICE SENSITIVE	99.59KB	Share
PTX PTX Broker Presentation
16/05/17	PRICE SENSITIVE	2.62MB	Share
PTX European Patent Granted for PTX-200
12/05/17	PRICE SENSITIVE	111.75KB	Share
PTX Kansas University Joins PTX's AML Trial
08/05/17	PRICE SENSITIVE	297.41KB	Share
PTX FDA Grants Orphan Drug Designation for PTX-200 in AML
01/05/17	PRICE SENSITIVE	137.25KB	Share
PTX March 2017 Appendix 4C - Quarterly
27/04/17	PRICE SENSITIVE	139.83KB	Share
PTX AML Update - Conference call with Principal Investigator
20/04/17		302.61KB	Share
PTX Successful Completion of Phase 1b Breast Cancer Trial
06/04/17	PRICE SENSITIVE	140.85KB	Share
PTX Trading Halt
04/04/17	PRICE SENSITIVE	319.66KB	Share
PTX Response to ASX Price Query
28/03/17	PRICE SENSITIVE	574.71KB	Share
PTX Three Additional US Patents Granted
16/03/17	PRICE SENSITIVE	95.03KB	Share
PTX ROTH Conference Presentation
15/03/17		3.28MB	Share
PTX PTX presentation for 29th Annual ROTH Conference
15/03/17		94.13KB	Share
PTX First Cohort Successfully Completed in Phase 1b/2 AML Trial
08/03/17	PRICE SENSITIVE	193.1KB	Share
PTX PTX to present at 29th Annual ROTH Conference
03/03/17		108.43KB	Share
PTX Appendix 4D and Half Year Financial Report
23/02/17	PRICE SENSITIVE	596.12KB	Share
PTX December 2016 Appendix 4C - Quarterly
25/01/17	PRICE SENSITIVE	158.04KB	Share
PTX Investor Presentation January 2017
11/01/17		2.87MB	Share
PTX PTX to present at Biotech Showcase 2017 in San Francisco
11/01/17		93.19KB	Share
PTX Change of Director's Interest Notices x4
21/12/16		469.28KB	Share
PTX Section 708A Cleansing Notice and Appendix 3B
21/12/16		650.69KB	Share
PTX Change of Registry Address
16/12/16		101.6KB	Share
PTX First Patient Dosed on Phase 1b/2 AML Trial
14/12/16	PRICE SENSITIVE	111KB	Share
PTX Phase 1b/2 Ovarian Trial Commences 2nd Dose Escalation
08/12/16	PRICE SENSITIVE	408.73KB	Share
PTX Results of Annual General Meeting
30/11/16		314.8KB	Share
PTX Change of Director's Interest Notice
09/11/16		263.27KB	Share
PTX Receipt of R&D Tax Rebate-PTX.AX
02/11/16	PRICE SENSITIVE	205.19KB	Share
PTX Notice of Annual General Meeting/Proxy Form-PTX.AX
28/10/16		1.48MB	Share
PTX September 2016 Appendix 4C - Quarterly-PTX.AX
28/10/16	PRICE SENSITIVE	395.63KB	Share
PTX Response to ASX Price Query-PTX.AX
19/10/16	PRICE SENSITIVE	716.25KB	Share
PTX First patient at Moffitt dosed in Phase 1b/2 breast trial-PTX.AX
26/09/16	PRICE SENSITIVE	225.64KB	Share
PTX Rodman & Renshaw Global Investment conference Presentation-PTX.AX
13/09/16		3.78MB	Share
PTX PTX presents at Rodman & Renshaw Investment conference-PTX.AX
13/09/16		272.42KB	Share
PTX Appendix 3B-PTX.AX
12/09/16		553.51KB	Share
PTX Appendix 4G and Corporate Governance Statement-PTX.AX
31/08/16		1.1MB	Share
PTX Appendix 4E and 2016 Annual Report-PTX.AX
31/08/16	PRICE SENSITIVE	800.39KB	Share
PTX Section 708A Cleansing Notice and Appendix 3B-PTX.AX
16/08/16		337.26KB	Share
PTX USPTO Grants Allowances for Two PTX-200 Patents-PTX.AX
04/08/16	PRICE SENSITIVE	269.27KB	Share
PTX Change of Director's Interest Notice-PTX.AX
27/07/16		266.91KB	Share
PTX Change to exercise price of options-PTX.AX
20/07/16	PRICE SENSITIVE	218.84KB	Share
PTX Change in substantial holding-PTX.AX
20/07/16		132.27KB	Share
PTX Amended Share Trading Policy-PTX.AX
20/07/16		438.69KB	Share
PTX June 2016 Appendix 4C - Quarterly-PTX.AX
20/07/16	PRICE SENSITIVE	197.07KB	Share
PTX Section 708A Cleansing Notice and Appendix 3B-PTX.AX
18/07/16		906.46KB	Share
PTX Shortfall Placement Oversubscribed-PTX.AX
12/07/16		157.86KB	Share
PTX Change in substantial holding for PTX,PTX-AEF.AX
07/07/16			Share
PTX Change in substantial holding for PTX,PTX-AEF.AX
07/07/16		247.35KB	Share
PTX Change in substantial holding-PTX.AX
05/07/16		221.72KB	Share
PTX Ceasing to be a substantial holder-PTX.AX
01/07/16		103.46KB	Share
PTX Change of Director's Interest Notices x2-PTX.AX
01/07/16		301.56KB	Share
PTX Completion of Entitlement Issue Allotment and Appendix 3B-PTX.AX
30/06/16		197.01KB	Share
PTX Entitlement Offer Closure and Shortfall Notification-PTX.AX
29/06/16		238.32KB	Share
PTX Becoming a substantial holder from AEF,AEF-PTX.AX
28/06/16			Share
PTX Becoming a substantial holder from AEF,AEF-PTX.AX
28/06/16		336.56KB	Share
PTX Becoming a substantial holder-PTX.AX
24/06/16		114.94KB	Share
PTX Change in substantial holding-PTX.AX
24/06/16			Share
PTX Change in substantial holding-PTX.AX
24/06/16		267.35KB	Share
PTX Tranche 2 Capital Raising Complete and Appendix 3B-PTX.AX
23/06/16			Share
PTX Tranche 2 Capital Raising Complete and Appendix 3B-PTX.AX
23/06/16		371.92KB	Share
PTX Results of Meeting-PTX.AX
22/06/16		354.47KB	Share
PTX Extension of Closing Date of Entitlement Offer-PTX.AX
16/06/16		78.97KB	Share
PTX Yale Joins PTX's Phase 1b/2 AML Clinical Trial-PTX.AX
15/06/16	PRICE SENSITIVE	269.24KB	Share
PTX Despatch of Pro-rata Rights Issue Offer Documents-PTX.AX
06/06/16		217.72KB	Share
PTX Replacement Entitlement Offer Prospectus-PTX.AX
03/06/16	PRICE SENSITIVE	1.14MB	Share

REFRESH

First 2 3 4

(20min delay)
Last 4.6¢		Change 0.001(2.22%)		Mkt cap ! $37.04M

Open	High	Low	Value	Volume
4.5¢	4.7¢	4.4¢	$26.47K	585.2K

Buyers (Bids)

No.	Vol.	Price($)
7	369667	4.4¢

Sellers (Offers)

Price($)	Vol.	No.
4.6¢	26283	1

View Market Depth

No.	Vol.	Price($)
7	369667	0.044
5	167824	0.043
3	564322	0.042
4	554780	0.041
13	900671	0.040

Price($)	Vol.	No.
0.046	26283	1
0.047	177991	4
0.048	332386	3
0.049	123571	3
0.050	48539	1

Last trade - 15.57pm 22/05/2024 (20 minute delay)


Last 4.5¢		Change 0.001 ( 2.17 %)
Open	High	Low	Volume
4.6¢	4.7¢	4.4¢	107148
Last updated 15.41pm 22/05/2024 ?

PTX (ASX) Chart

PRESCIENT THERAPEUTICS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories